Multi-day nerve block injection for post-surgical pain
Raised to date
$1.3M
of $3.4M offered across 1 Form D filing
InSitu Biologics is a near-clinical-stage company developing injectable sustained-release drug delivery for localized, site-specific treatment. Its platform forms a reservoir at the injection site and releases drug over several days. The lead product, INSB200, is a sustained-release ropivacaine formulation for peripheral nerve blocks targeting three to five days of post-surgical pain relief from one injection, with an IND planned for Q1 2027 and a Phase 1/2 bunionectomy trial in Q2 2027. The company also has a license agreement with Mayo Clinic to co-develop anti-cancer therapeutics on the platform.
A single injection that forms a local drug reservoir and releases anesthetic over multiple days at the surgical site.
$3.4M debt round, Aug 2026: $1.3M sold, $2.1M still open
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Oct 14, 2026 | Debt | $1.3M/ $3.4M | Form D/A |
Post-surgical analgesic (preclinical)
Investigational sustained-release formulation of ropivacaine for peripheral nerve blocks after surgery.
Built for
Surgeons, anesthesiologists and hospitals managing post-operative pain
